Edwards Lifesciences, LLC recalls Optisite Arterial Cannula
The stated reason: due to complaints received for 3mm to 4mm section wire exposed/protruding from the outside of the cannula body.
Edwards Lifesciences, LLC began a medical device recall on May 14, 2025 whose reported distribution included Ohio. FDA
What the record shows
FDA graded it Class I — a reasonable probability that use will cause serious health consequences or death. Quantity affected: 27022. The recall is listed as ongoing. FDA
Context
By the numbers
- Date of record: May 14, 2025 FDA
- Recall number: Z-2080-2025 FDA
- Recalls in this action: 1 FDA
- Recalling firm: Edwards Lifesciences, LLC FDA
- Product: Brand Name: Optisite Arterial Cannula Product Name: Optisite Arterial Cannula Model/Catalog Number: OPTI16 Software… FDA
- Reason for recall: due to complaints received for 3mm to 4mm section wire exposed/protruding from the outside of the cannula body. FDA
Assembled mechanically from the source filing and The Lantern's own record database — no AI-written prose. Every figure above appears verbatim in the cited record, which is linked on this page. FDA
Sources
The source filing
| Recall number | Z-2080-2025 |
|---|---|
| Recalls in this action | 1 |
| Recalling firm | Edwards Lifesciences, LLC |
| Product | Brand Name: Optisite Arterial Cannula Product Name: Optisite Arterial Cannula Model/Catalog Number: OPTI16 Software Version: N/A Product Description: Cardiac cannula. The Edwards OptiSite Arterial Perfusion Cannluae provides or establishes arterial perfusion in the extracorporeal circuit for d 6 hours. Component: No. |
| Reason for recall | due to complaints received for 3mm to 4mm section wire exposed/protruding from the outside of the cannula body. |
| Classification | Class I — a reasonable probability that use will cause serious health consequences or death |
| Recall type | medical device |
| Quantity | 27022 |
| Status | Ongoing |
| Voluntary or mandated | Voluntary: Firm initiated |
| Initiated | 20250514 |
| Reported | 20250716 |
| Distribution | Worldwide - US Nationwide distribution including in the states of ALABAMA, ARIZONA, ARKANSAS, CALIFORNIA, COLORADO, CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, FLORIDA, GEORGIA, HAWAII, IDAHO, ILLINOIS, INDIANA, IOWA, KANSAS, KENTUCKY, LOUISIANA, MAINE, MARYLAND, MASSACHUSETTS, MICHIGAN, MINNESOTA, MISSISSIPPI, MISSOURI, MONTANA, NEBRASKA, NEVADA, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEW Y |
| Firm location | Irvine, CA, United States |
Published by U.S. Food and Drug Administration (openFDA). This is the agency's public filing as The Lantern received it, shown with its fields named in plain English.